Drug Search Results
More Filters [+]

CEP-1374

Alternative Names: cep-1374, cep-1347, cep1347
Latest Update: 2023-09-05
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: JNK Inhibitor

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CEP-1374

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Parkinson's Disease

Phase 2: Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2004-002812-27

P2

Completed

Asthma

2005-12-17

C1347c/204/PD/US-CA

P3

Terminated

Parkinson's Disease

2005-08-01

Recent News Events